Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Copper

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    163 result(s) found for: Copper. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2020-005266-34 Sponsor Protocol Number: UX701-CL301 Start Date*: 2022-02-11
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Seamless, Adaptive, Safety, Dose-finding, and Phase 3 Clinical Study of UX701 AAV-mediated Gene Transfer for the Treatment of Wilson Dis...
    Medical condition: Wilson disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000905-57 Sponsor Protocol Number: wilson12345 Start Date*: 2019-04-17
    Sponsor Name:The Department of Hepatology and Gastroenterology, Aarhus University Hospital
    Full Title: Efficacy of zinc on human gut copper uptake depending on zinc type and dose regimen quantified with 64CuCl2 PET/CT-scan
    Medical condition: Healthy volunteers (Wilson's disease)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001386-81 Sponsor Protocol Number: 2016-1-DSF-MBC Start Date*: 2019-01-11
    Sponsor Name:Univerzita Palackého v Olomouci
    Full Title: PHASE II OPEN LABELED TRIAL OF DISULFIRAM WITH COPPER IN METASTATIC BREAST CANCERS.
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004604-33 Sponsor Protocol Number: TR-004 Start Date*: 2021-02-23
    Sponsor Name:Univar Solutions, B.V.
    Full Title: Open label, Multicenter, Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) and to Investigate the Efficacy and Safety in Wilson’s Di...
    Medical condition: Wilson Disease
    Disease: Version SOC Term Classification Code Term Level
    22.1 10010331 - Congenital, familial and genetic disorders 10019819 Hepato-lenticular degeneration PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005832-31 Sponsor Protocol Number: ALXN1840-HV-Cu-Absorption Start Date*: 2021-04-13
    Sponsor Name:Alexion Pharmaceuticals Inc.
    Full Title: Efficacy of ALXN1840 on human hepatic copper uptake quantified with 64CuCl2 PET/CT-scan.
    Medical condition: Healthy Volunteers (Wilson's disease)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000235-30 Sponsor Protocol Number: GPRI-21001-COV Start Date*: 2021-02-09
    Sponsor Name:General Practitioners Research Institute
    Full Title: COVID-19 Primary care Platform for Early treatment and Recovery (COPPER) Study: an open-label adaptive platform randomized controlled trial
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001703-41 Sponsor Protocol Number: WTX101-201 Start Date*: 2014-08-18
    Sponsor Name:Alexion Pharmaceuticals, INC.
    Full Title: A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older with an Extension Pha...
    Medical condition: Wilson Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000102-25 Sponsor Protocol Number: ALXN1840-WD-Cu-Excretion Start Date*: 2021-04-09
    Sponsor Name:Aarhus University Hospital
    Full Title: Efficacy of ALXN1840 on human biliary copper excretion quantified with 64CuCl2 PET/MR-scan
    Medical condition: Wilson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000963-22 Sponsor Protocol Number: VTX-801_CLN_001 Start Date*: 2021-10-18
    Sponsor Name:Vivet Therapeutics SAS
    Full Title: A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson’s Disease
    Medical condition: Wilson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10047988 Wilson's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003876-29 Sponsor Protocol Number: GMPO-131-002 Start Date*: 2017-05-16
    Sponsor Name:Orphalan
    Full Title: CHELATE STUDY: Trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s disease
    Medical condition: Wilson's disease (WD) is a life-threatening inborn error of copper metabolism leading to an excessive copper accumulation, mainly in the liver or brain, causing hepatic and neurologic severe symptoms.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004135-36 Sponsor Protocol Number: WTX101-301 Start Date*: 2018-03-23
    Sponsor Name:Wilson Therapeutics AB
    Full Title: A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older...
    Medical condition: Wilson Disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) CZ (Prematurely Ended) FR (Completed) AT (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) PT (Completed) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001104-41 Sponsor Protocol Number: ALXN1840-WD-204 Start Date*: 2020-07-22
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, open-label study to assess copper and molybdenum balance in participants with Wilson disease treated with ALXN1840
    Medical condition: Wilson Disease (WD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-001015-82 Sponsor Protocol Number: ALXN1840-WD-302 Start Date*: 2021-11-26
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A multicenter, randomized, controlled, open-label, rater-blinded study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ALXN1840 versus standard of care in pediatric particip...
    Medical condition: Wilson Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001972-12 Sponsor Protocol Number: AA1817 Start Date*: 2019-09-13
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: A phase 1b/2 open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors and advanced breast cancer
    Medical condition: in phase 1b part: advanced and/or treatment refractory solid malignancies in phase 2 part : advanced or metastatic HER2-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070308 Refractory cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002748-25 Sponsor Protocol Number: KFE19.17 Start Date*: 2019-10-11
    Sponsor Name:Department of Oncology, Odense Universitetshospital
    Full Title: Repurposing disulfiram as treatment for metastatic colorectal cancer An investigator initiated clinical phase II trial
    Medical condition: Metastatic, non-resectable and irinotecan-resistant colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002242-17 Sponsor Protocol Number: B00844 Start Date*: 2020-07-30
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: A randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy.
    Medical condition: Hypertrophic Cardiomyopathy (HCM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-000167-16 Sponsor Protocol Number: DIRECT-2016 Start Date*: 2016-05-19
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: DIsulfiram REsponse as add-on to ChemoTherapy in recurrent Glioblastoma: A randomized controlled trial
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003711-60 Sponsor Protocol Number: ALXN1840-WD-205 Start Date*: 2021-01-15
    Sponsor Name:Alexion Pharmaceuticals, Inc
    Full Title: A Phase 2, single-arm, pathologist-blinded study using liver biopsy specimens to assess copper concentration and histopathologic changes in patients with Wilson disease who are treated with ALXN184...
    Medical condition: Wilson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004445-32 Sponsor Protocol Number: TR-001PK Start Date*: 2013-03-06
    Sponsor Name:Univar BV
    Full Title: A Phase I Pharmacokinetic Profiling Study in Patients Receiving Trientine Dihydrochloride for the Treatment of Wilson’s Disease
    Medical condition: Wilson disease, also known as hepatolenticular degeneration, a rare autosomal, recessively inherited disorder which results in chronic copper intoxication.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001957-16 Sponsor Protocol Number: BREAST-SK-001 Start Date*: 2019-10-31
    Sponsor Name:Národný onkologický ústav
    Full Title: Phase II study of Vinorelbine, cisplatin, disulfiram and copper in CTC_EMT positive refractory metastatic breast cancer.
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 22:22:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA